Cargando…

Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways

Berberine (BBR) is an isoquinoline alkaloid, reported to have multiple pharmacological functions. However, its effects against CCl(4)-induced oxidative damage remain poorly studied. Therefore, the present study investigated the protective action of BBR, and its antioxidant mechanisms, against CCl(4)...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Chun-Yang, Sun, Tao-Tao, Xv, Guang-Pei, Wang, Si-Si, Gu, Jin-Gang, Liu, Cui-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755230/
https://www.ncbi.nlm.nih.gov/pubmed/31432116
http://dx.doi.org/10.3892/mmr.2019.10551
_version_ 1783453188501798912
author Han, Chun-Yang
Sun, Tao-Tao
Xv, Guang-Pei
Wang, Si-Si
Gu, Jin-Gang
Liu, Cui-Yan
author_facet Han, Chun-Yang
Sun, Tao-Tao
Xv, Guang-Pei
Wang, Si-Si
Gu, Jin-Gang
Liu, Cui-Yan
author_sort Han, Chun-Yang
collection PubMed
description Berberine (BBR) is an isoquinoline alkaloid, reported to have multiple pharmacological functions. However, its effects against CCl(4)-induced oxidative damage remain poorly studied. Therefore, the present study investigated the protective action of BBR, and its antioxidant mechanisms, against CCl(4)-induced liver injury in rats. A total of 48 rats were randomly arranged into six groups: Control; model; positive control (PC); BBR low-dose (BL); BBR middle-dose (BM); and BBR high-dose (BH). The BL, BM and BH animals received BBR (5, 10 and 15 mg/kg by weight, respectively) orally for 7 consecutive days. Rats in the PC group were given silymarin (150 mg/kg), and the control and model groups were administered distilled water orally. At the end of the experiment, blood samples and livers were collected. To measure the liver biochemical indices, the reactive oxygen species (ROS) generation and the expression levels of related genes and protein, the following methods were used: An automatic biochemical analyzer; flow cytometry; spectrophotometry; reverse transcription-quantitative PCR; western blotting; and hematoxylin and eosin staining. The results revealed that BBR significantly decreased the serum levels of alanine transaminase, aspartate transaminase and alkaline phosphatase, and increased those of glutathione and superoxide dismutase, but decreased malondialdehyde activity in hepatic tissue, and significantly decreased the reactive oxygen species level in hepatocytes. In hepatic tissue, the expressions of nuclear factor erythroid 2-related factor 2 (Nrf2), kelch-like ECH-associated protein 1 (Keap-1), NAD(P)H quinone dehydrogenase 1 (NQO-1), heme oxygenase 1 (HO-1), Bcl-2 and Bcl-xL mRNA, and HO-1 protein were elevated, and the expression of p53 mRNA was decreased, particularly in the BH group (15 mg/kg). In conclusion, BBR exerts a protective action against CCl(4)-induced acute liver injury in rats via effectively regulating the expression of Nrf2-Keap1-antioxidant responsive element-related genes and proteins, and inhibiting p53 pathway-mediated hepatocyte apoptosis.
format Online
Article
Text
id pubmed-6755230
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-67552302019-09-25 Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways Han, Chun-Yang Sun, Tao-Tao Xv, Guang-Pei Wang, Si-Si Gu, Jin-Gang Liu, Cui-Yan Mol Med Rep Articles Berberine (BBR) is an isoquinoline alkaloid, reported to have multiple pharmacological functions. However, its effects against CCl(4)-induced oxidative damage remain poorly studied. Therefore, the present study investigated the protective action of BBR, and its antioxidant mechanisms, against CCl(4)-induced liver injury in rats. A total of 48 rats were randomly arranged into six groups: Control; model; positive control (PC); BBR low-dose (BL); BBR middle-dose (BM); and BBR high-dose (BH). The BL, BM and BH animals received BBR (5, 10 and 15 mg/kg by weight, respectively) orally for 7 consecutive days. Rats in the PC group were given silymarin (150 mg/kg), and the control and model groups were administered distilled water orally. At the end of the experiment, blood samples and livers were collected. To measure the liver biochemical indices, the reactive oxygen species (ROS) generation and the expression levels of related genes and protein, the following methods were used: An automatic biochemical analyzer; flow cytometry; spectrophotometry; reverse transcription-quantitative PCR; western blotting; and hematoxylin and eosin staining. The results revealed that BBR significantly decreased the serum levels of alanine transaminase, aspartate transaminase and alkaline phosphatase, and increased those of glutathione and superoxide dismutase, but decreased malondialdehyde activity in hepatic tissue, and significantly decreased the reactive oxygen species level in hepatocytes. In hepatic tissue, the expressions of nuclear factor erythroid 2-related factor 2 (Nrf2), kelch-like ECH-associated protein 1 (Keap-1), NAD(P)H quinone dehydrogenase 1 (NQO-1), heme oxygenase 1 (HO-1), Bcl-2 and Bcl-xL mRNA, and HO-1 protein were elevated, and the expression of p53 mRNA was decreased, particularly in the BH group (15 mg/kg). In conclusion, BBR exerts a protective action against CCl(4)-induced acute liver injury in rats via effectively regulating the expression of Nrf2-Keap1-antioxidant responsive element-related genes and proteins, and inhibiting p53 pathway-mediated hepatocyte apoptosis. D.A. Spandidos 2019-10 2019-08-06 /pmc/articles/PMC6755230/ /pubmed/31432116 http://dx.doi.org/10.3892/mmr.2019.10551 Text en Copyright: © Han et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Han, Chun-Yang
Sun, Tao-Tao
Xv, Guang-Pei
Wang, Si-Si
Gu, Jin-Gang
Liu, Cui-Yan
Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways
title Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways
title_full Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways
title_fullStr Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways
title_full_unstemmed Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways
title_short Berberine ameliorates CCl(4)-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways
title_sort berberine ameliorates ccl(4)-induced liver injury in rats through regulation of the nrf2-keap1-are and p53 signaling pathways
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755230/
https://www.ncbi.nlm.nih.gov/pubmed/31432116
http://dx.doi.org/10.3892/mmr.2019.10551
work_keys_str_mv AT hanchunyang berberineamelioratesccl4inducedliverinjuryinratsthroughregulationofthenrf2keap1areandp53signalingpathways
AT suntaotao berberineamelioratesccl4inducedliverinjuryinratsthroughregulationofthenrf2keap1areandp53signalingpathways
AT xvguangpei berberineamelioratesccl4inducedliverinjuryinratsthroughregulationofthenrf2keap1areandp53signalingpathways
AT wangsisi berberineamelioratesccl4inducedliverinjuryinratsthroughregulationofthenrf2keap1areandp53signalingpathways
AT gujingang berberineamelioratesccl4inducedliverinjuryinratsthroughregulationofthenrf2keap1areandp53signalingpathways
AT liucuiyan berberineamelioratesccl4inducedliverinjuryinratsthroughregulationofthenrf2keap1areandp53signalingpathways